TRASICOR RETARD 80 mg depottabletti ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

trasicor retard 80 mg depottabletti

novartis pharma stein ag - oxprenololi hydrochloridum - depottabletti - 80 mg - oksprenololi

SPESICOR 25 mg tabletti ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

spesicor 25 mg tabletti

oy leiras finland ab - metoprololi tartras - tabletti - 25 mg - metoprololi

POSICOR 50 mg tabletti ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

posicor 50 mg tabletti

roche registration limited - mibefradili dihydrochloridum - tabletti - 50 mg - mibefradiili

POSICOR 100 mg tabletti ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

posicor 100 mg tabletti

roche registration limited - mibefradili dihydrochloridum - tabletti - 100 mg - mibefradiili

Budesonide/Formoterol Teva Pharma B.V. ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

budesonide/formoterol teva pharma b.v.

teva pharma b.v. - budesonide, formoterol - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - budesonidi / formoterol teva pharma b. on tarkoitettu aikuisille vain 18-vuotiaille ja vanhemmille. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Airexar Spiromax ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

airexar spiromax

teva b.v. - salmeterol fluticasone propionate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - airexar spiromax on tarkoitettu käytettäväksi vain 18-vuotiailla ja sitä vanhemmilla aikuisilla. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. krooninen obstruktiivinen keuhkosairaus (copd)airexar spiromax on tarkoitettu oireenmukaiseen hoitoon potilailla, joilla on copd, fev1.